Tibor Keler
Founder chez CELLDEX THERAPEUTICS, INC.
Fortune : 308 773 $ au 31/03/2024
Profil
Tibor Keler is the founder of Celldex Therapeutics, Inc. which was founded in 1983.
He held the title of Chief Scientific Officer & Executive VP.
Dr. Keler's current job is as Chief Scientific Officer, VP-Research & Discovery at Celldex Research Corp.
since 2003.
Dr. Keler's former jobs include Senior Director-Preclinical Development at Medarex, Inc. from 1993 to 2004, Chief Scientific Officer & Senior Vice President at AVANT Immunotherapeutics, Inc. in 2008, and Chief Scientific Officer, VP-Research & Discovery at Celldex Therapeutics, Inc. (Old) from 2003 to 2008.
Dr. Keler's education includes a doctorate from the University of Pennsylvania and undergraduate and graduate degrees from Drexel University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2023 | 7 357 ( 0,01% ) | 308 773 $ | 31/03/2024 |
Postes actifs de Tibor Keler
| Sociétés | Poste | Début |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Founder | 01/01/1983 |
Celldex Research Corp.
 Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Chief Tech/Sci/R&D Officer | 01/05/2003 |
Anciens postes connus de Tibor Keler
| Sociétés | Poste | Fin |
|---|---|---|
Celldex Therapeutics, Inc. (Old)
 Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Chief Tech/Sci/R&D Officer | 01/10/2008 |
AVANT Immunotherapeutics, Inc.
 AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Chief Tech/Sci/R&D Officer | 01/10/2008 |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Corporate Officer/Principal | 01/03/2004 |
Formation de Tibor Keler
| University of Pennsylvania | Doctorate Degree |
| Drexel University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Entreprise privées | 4 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Therapeutics, Inc. (Old)
Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
Celldex Research Corp.
Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
